CCKAR and pancreatic neoplasm: Their data showed that this VISA system exhibited significant antitumor effects on pancreatic cancer and prolonged survival time of mice in multiple xenograft and syngeneic orthotopic murine models of pancreatic tumors, including the enhanced average tumor-specific CCKAR promoter activity of 600–700 times and the increased gene therapy specificity index, as well as prolonged expression time of 3–4 times.